PUBLIC RELEASE DATE: 1-Sep-2014 Contact: Jenny Orton press@lshtm.ac.uk 44-207-927-2802 London School of Hygiene & Tropical Medicine Doctors and researchers will be able to easily identify different types of tuberculosis (TB) thanks to a new genetic barcode devised by scientists from the London School of Hygiene & Tropical Medicine. The bacteria that cause the deadly respiratory disease have evolved into families of strains, or lineages, which may affect people differently. To help identify the different origins and map how tuberculosis moves around the world, spreading from person to person through the air, the research team studied over 90,000 genetic mutations. According to the study published in Nature Communications the researchers found that just 62 mutations are needed to code the global family of strains. Dr Taane Clark, Reader in Genetic Epidemiology and Statistical Genomics at the London School of Hygiene & Tropical Medicine, who led the study, said: "There is increasing interest in new technologies that can assist those treating tuberculosis patients. "This new barcode can be easily implemented and used to determine the strain-type that is a surrogate for virulence. "We are making this information available to the doctors and scientists working with tuberculosis so that they can more easily … Continue reading →

John Hwa is a professor of medicine and the director of cardiovascular pharmacogenetics at Yale School of Medicine. Along with Dartmouth genetics professor Jason H. Moore, Hwa recently coauthored an editorial in the journal Current Molecular Medicine. The article, titled Pharmacogenetics and Molecular Medicine: So Close and Yet So Far introduces a new review series of eight articles contributed by different researchers in the field of pharmacogenomics. The News sat down with Hwa and his colleague, Yale postdoctoral fellow Jeremiah Stitham, to understand the latest advances in the field. Q. How would you define the fields of pharmacogenomics and personalized medicine to the general public? What are the basic underlying principles and ideas? H. About 100,000 people die each year from adverse side effects to medications, and millions of others have some sort of harmful drug reaction. The idea of pharmacogenetics is to try and figure out, based on genetics, who is going to suffer problems and who will benefit the most from taking a particular drug. Though there are actually many definitions out there, the simplest definition is that it is a combination of pharmacology and genetics: pharmacogenetics. It is the use of genetic data to understand how a … Continue reading →

PALO ALTO, Calif., Sep 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Cellular Biomedicine Group Inc. CBMG, +16.29% ("CBMG" or the "Company"), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of a study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for Cartilage Defects (CD) resulting from osteoarthritis (OA) or sports injury. Both arthroscopy and the use of magnetic resonance imaging (MRI) will be deployed to further demonstrate the regenerative efficacy of ReJoinTM on cartilage defects. "In light of the promising Knee Osteoarthritis Phase IIa six month follow-up results we decided to explore the efficacy of our proprietary ReJoinTM therapy on an additional orthopedic indication, Cartilage Defects (CD)," said Dr. William (Wei) Cao, Chief Executive Officer of the Company. "We are thankful for the approval by the ethics committee of Shanghai Ninth People's Hospital for this exploratory clinical research, and very much look forward to finding the promise of ReJoinTM therapy on CD. The repair of CD would greatly improve the quality of life for CD patients, allowing for greater mobility, flexibility and less pain." About the Study The clinical study is a single-blind, randomly assigned, controlled clinical research … Continue reading →

Albany, New York (PRWEB) September 02, 2014 Nanomedicine is essentially based on the medical application of nanotechnology in diagnosing, treating and/or prevention of diseases and infections. Nanotechnology-based drugs and treatments are applied for treating cardiovascular, neurological, and oncology diseases. Nanomedicine is based on the utilization of knowledge pertaining to various nanoparticles, their medical usages, and their actions within the human body. There still exists considerable scope for research in this domain, and scientists are currently engaged in further studying the treatment-worthiness of a number of nanoparticles such as fullerenes, dendrimers, drug conjugates, and nano crystals. It is important to note that this area of medicine is still in its nascent stage mainly because it is a niche research area and it receives comparatively less research funding. To browse through the ToC or purchase the market report on Nanomedicine Market, please visit: http://www.transparencymarketresearch.com/nanomedicine-market.html According to the market research report by Transparency Market Research, oncology was the largest application segment within the nanomedicine market with a total share of 38%. This is attributed to the large scale focus on developing drugs and treatments for cancer, and the fact that approved nanomedicine drugs also exist in the market. Get report sample PDF copy … Continue reading →